GemPharmatech Co Ltd
688046
Company Profile
Business description
GemPharmatech Co Ltd is a provider of genetically engineered mouse models and services to preclinical research and development communities. The company develops mouse models with independent intellectual property rights based on technical platforms such as gene editing, stem cells, phenotypic analysis, efficacy analysis, and sterile animals, and carries out one-stop services such as model customization, customized breeding, and functional efficacy analysis.
Contact
No. 12, Xuefu Road
Jiangbei New District, Jiangsu Province
Nanjing210032
CHNT: +86 2558243997
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
1,578
Stocks News & Analysis
stocks
Strong guidance from undervalued ASX share
Shares surged after the announcement of first half fiscal 2026 guidance.
stocks
TSMC earnings: Refining guidance and expansion plans amid strong AI demand
We maintain our fair value estimate for TSMC stock.
stocks
Unconventional wisdom: A top performing ‘AI share’ accidently ended up in my portfolio
Trying to make sense of a share caught up in irrational exuberance.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,168.70 | 33.00 | 0.36% |
| CAC 40 | 8,425.13 | 0.00 | 0.00% |
| DAX 40 | 24,702.24 | 547.77 | 2.27% |
| Dow JONES (US) | 49,447.43 | 868.71 | 1.79% |
| FTSE 100 | 10,667.63 | 77.64 | 0.73% |
| HKSE | 26,160.33 | 233.93 | -0.89% |
| NASDAQ | 24,468.48 | 365.78 | 1.52% |
| Nikkei 225 | 58,475.90 | 1,042.44 | -1.75% |
| NZX 50 Index | 12,905.67 | 160.39 | -1.23% |
| S&P 500 | 7,126.06 | 84.78 | 1.20% |
| S&P/ASX 200 | 8,946.90 | 36.80 | 0.41% |
| SSE Composite Index | 4,051.43 | 4.12 | -0.10% |